Monograph

M05BX04 - Denosumab

Not porphyrinogenic

Rationale

Denosumab is not metabolised by CYP enzymes, and does not inhibit or induce CYP3A4.

Chemical description

Denosumab is human monoclonal antibody (IgG2).

Therapeutic characteristics

Denosumab is indicated for the treatment of osteoporosis at increased risk of fractures and treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Common side effects are urinary tract infections, upper respiratory tract infections, obstipation and pain in extremity.

Metabolism and pharmacokinetics

Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids (SPC). Denosumab showed no effect on the pharmacokinetics of midazolam (a CYP3A4 substrate). This indicates that denosumab does not inhibit or induce CYP3A4 (SPC).

Similar drugs

Explore alternative drugs in similar therapeutic classes M05B / M05BX or go back.

References

#	Citation details	PMID
*	Summary of Product Characteristics
1.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Denosumab.

Citation details

PMID

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Denosumab.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames

Jubbonti 60 mg oplossing voor injectie in een voorgevulde spuit · Obodence 60 mg oplossing voor injectie in een voorgevulde spuit · Osenvelt 120 mg oplossing voor injectie · Prolia 60 mg oplossing voor injectie in een voorgevulde spuit · Stoboclo 60 mg oplossing voor injectie in een voorgevulde spuit · Wyost 120 mg oplossing voor injectie · Xbryk 120 mg oplossing voor injectie · Xgeva 120 mg oplossing voor injectie · Xgeva 120 mg oplossing voor injectie in voorgevulde spuit

Jubbonti · Jubbonti 60 mg/ml sol. inj. s.c. ser. pr?remplie · Obodence · Obodence 60 mg sol. inj. s.c. ser. pr?remplie · Prolia · Prolia 60 mg sol. inj. s.c. ser. pr?remplie · Wyost 120 mg sol. inj. s.c. flac. · Xgeva · Xgeva 120 mg sol. inj. s.c. flac. · Xgeva 120 mg sol. inj. s.c. ser. pr?remplie

Jubbonti 60 mg Solucion Inyectable en Jeringa Precargada · PROLIA 60 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA · Wyost 120 mg Solucion Inyectable · XGEVA 120 mg SOLUCION INYECTABLE · XGEVA 120mg solucion inyectable